THESEUS PHARMACEUTICALS, INC.
THESEUS PHARMACEUTICALS, INC. logo
THRX

THESEUS PHARMACEUTICALS, INC. (THRX)

$12.132.8%

Market is closed
– opens on 8 PM, 30 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$11.6001
Day's Range
$12.5422
$4.01
52-Week Range
$15.21
1 month return139.72%
3 month return125.46%
1 year return31.42%
5 year return34.71%

Analyst Recommendation

based on 11 analysts ratings

Buy
90%
Buy
9%
Hold
0%
Sell

Based on 11 Wall street analysts offering stock ratings for THESEUS PHARMACEUTICALS, INC.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 79.97%

Current

$12.13

Target

$21.83

Recommendation Trend

Based on 11 analyst

Current1M Ago3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization456.8M
Book Value$5.71
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-1.76
Wall Street Target Price21.83

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)1.04
Enterprise Value10.8M
Enterprise Value/Revenue0.0
Enterprise Value/Ebitda-0.23

Technicals

50 Day MA7.07
200 Day MA7.09

Institutional Holdings

Orbimed Advisors, LLC

44.02%

FMR Inc

12.41%

Foresite Capital Management V, LLC

8.62%

T. Rowe Price Associates, Inc.

3.57%

Foresite Capital Opportunity Management V, LLC

2.48%

Boxer Capital LLC

2.3%

Company Information

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
OrganizationTHESEUS PHARMACEUTICALS, INC.
Employees26
CEODr. Iain D. Dukes D.Phil., DPHIL, M.A.
IndustryServices

Discover more

Frequently Asked Questions

What is THESEUS PHARMACEUTICALS, INC. share price today?

Can Indians buy THESEUS PHARMACEUTICALS, INC. shares?

How can I buy THESEUS PHARMACEUTICALS, INC. shares from India?

Can Fractional shares of THESEUS PHARMACEUTICALS, INC. be purchased?

What are the documents required to start investing in THESEUS PHARMACEUTICALS, INC. stocks?

What are today’s High and Low prices of THESEUS PHARMACEUTICALS, INC.?

What are today’s traded volumes of THESEUS PHARMACEUTICALS, INC.?

What is today’s market capitalisation of THESEUS PHARMACEUTICALS, INC.?

What is the 52 Week High and Low Range of THESEUS PHARMACEUTICALS, INC.?

How much percentage THESEUS PHARMACEUTICALS, INC. is down from its 52 Week High?

How much percentage THESEUS PHARMACEUTICALS, INC. is up from its 52 Week low?

What are the historical returns of THESEUS PHARMACEUTICALS, INC.?

Who is the Chief Executive Officer (CEO) of THESEUS PHARMACEUTICALS, INC.?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*